Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -628.14% is 29% above its 5-year average of -884.17%, near the low end of its 5-year range (-1961.25%–7168.81%).
22.52% above its 12-month average of -810.67%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1444.84%.
EBITDA MARGIN
-628.14%
EBITDA MARGIN AVG TTM
-810.67%
EBITDA MARGIN AVG 3Y
-889.29%
EBITDA MARGIN AVG 5Y
-884.17%
EBITDA MARGIN AVG 10Y
-570.76%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+22.52%
CURRENT VS 3Y AVG
+29.37%
CURRENT VS 5Y AVG
+28.96%
CURRENT VS 10Y AVG
-10.05%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Intellia Therapeutics, Inc.
Market Cap
$1.71B
EBITDA Margin
-628.14%
TTM Avg
-810.67%
3Y Avg
-889.29%
5Y Avg
-884.17%
Market Cap
$1.74B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$2.16B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$1.00B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$2.52B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$2.76B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$474.59M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$394.23M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | $1.71B | -628.14% | -810.67% | -889.29% | -884.17% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 16.41% | 1.22% | -1.65% | 4.31% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 3.96% | -13.21% | -146.19% | -104.68% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | -270.04% | -444.88% | -365.27% | -89273.54% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 22.42% | 17.70% | -0.76% | -37.34% |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | 0.24% | -1.36% | -6.49% | -5.53% |
| NRC Health (NRC)vs › | $458.62M | 21.99% | 25.40% | 28.98% | 31.97% |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | -48.80% | -44.09% | -45.35% | -45.35% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.86M | N/A | N/A | N/A | N/A |
Gross Margin
76.5%
EBITDA Margin
-628.1%
Operating Margin
-651.7%
Net Margin
-672.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1444.84% |
| 2026-03-31 | -653.44% |
| 2025-12-31 | -427.22% |
| 2025-09-30 | -773.04% |
| 2025-06-30 | -754.81% |
| 2025-03-31 | -711.55% |
| 2024-12-31 | -1039.93% |
| 2024-09-30 | -1560.33% |
| 2024-06-30 | -1961.25% |
| 2024-03-31 | -385.32% |
| 2023-12-31 | 7168.81% |
| 2023-09-30 | -1074.19% |
| 2023-06-30 | -957.51% |
| 2023-03-31 | -871.87% |
| 2022-12-31 | -796.11% |
| 2022-09-30 | -780.79% |
| 2022-06-30 | -687.56% |
| 2022-03-31 | -1266.37% |
| 2021-12-31 | -610.98% |
| 2021-09-30 | -974.56% |
| 2021-06-30 | -1028.75% |
| 2021-03-31 | -695.64% |
| 2020-12-31 | -618.61% |
| 2020-09-30 | -119.26% |
| 2020-06-30 | -193.49% |
| 2020-03-31 | -243.94% |
| 2019-12-31 | -257.91% |
| 2019-09-30 | -225.56% |
| 2019-06-30 | -235.10% |
| 2019-03-31 | -215.76% |
| 2018-12-31 | -247.70% |
| 2018-09-30 | -309.76% |
| 2018-06-30 | -293.37% |
| 2018-03-31 | -286.76% |
| 2017-12-31 | -358.16% |
| 2017-09-30 | -206.16% |
| 2017-06-30 | -258.68% |
| 2017-03-31 | -197.72% |
| 2016-12-31 | -185.13% |
| 2016-09-30 | -152.64% |
| 2016-06-30 | -159.27% |
| 2016-03-31 | -366.18% |
| 2015-12-31 | -316.54% |
| 2015-09-30 | -189.87% |
| 2015-06-30 | -243.65% |
| 2015-03-31 | -90.36% |
